Skip to main content

Summary

for females ages 18–130 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

AZD1775 in combination with carboplatin, paclitaxel, gemcitabine, or PLD.

Official Title

A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Details

This is an open-label, four-arm lead-in safety and efficacy study in which AZD1775 will be combined in four separate treatment arms as follows: AZD1775 plus gemcitabine (Arm A); AZD1775 plus weekly paclitaxel (Arm B); AZD1775 plus carboplatin (Arm C); and AZD1775 plus PLD (Arm D). A subset of patients will be evaluated for the safety assessment of each treatment arm.

The AZD1775 plus paclitaxel arm (Arm B) will enrol approximately 30 additional patients at selected sites as part of a further efficacy evaluation based on emerging data that suggests clinical activity.

In addition, the AZD1775 plus carboplatin arm (Arm C) will enrol approximately 23 patients overall at selected sites as part of a further efficacy evaluation based on emerging data that suggests clinical activity.

To further optimise the dosing schedule of AZD1775 in Arm C, a safety expansion arm (referred to as Arm C2) of approximately 12 additional patients will be enrolled at selected sites to explore emerging pre-clinical and clinical data that suggest that prolonged AZD1775 exposure may increase the clinical activity.

Keywords

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Peritoneal Neoplasms Paclitaxel Gemcitabine Albumin-Bound Paclitaxel Carboplatin

Eligibility

For females ages 18–130

Inclusion

  • Has read and understands the informed consent form (ICF) and has given written IC prior to any study specific procedures.
  • Histologic or cytologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Progressed within 6 months of completing at least 4 cycles of a first-line platinum-containing regimen for Stage III/IV disease. Patients with refractory disease(progression during platinum-containing therapy) are ineligible.
  • No more than 2-4 prior treatment regimens for Stage III/IV disease, defined as investigational, chemotherapy, hormonal, biologic, or targeted therapy.
  • Prior doxorubicin (or other anthracycline) at a cumulative dose of ≤ 360 mg/m² or cumulative epirubicin dose of ≤ 720 mg/m² (calculated using doxorubicin equivalent doses: 1 mg of doxorubicin = 1 mg PLD = 0.3 mg mitoxantrone = 0.25 mg idarubicin).Subjects without any prior anthracycline exposure can also be included. Applies to Arm D only.
  • At least 1 measurable lesion according to RECIST v1.1.
  • Any prior palliative radiation therapy must be completed at least 7 days prior to start of study treatment and patients must have recovered from any acute adverse effects prior to start of study treatment.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 - 1.
  • Baseline Laboratory Values:
  • ANC ≥1500/μL
  • HgB ≥ 9 g/dL with no blood transfusions in the past 28 days
  • Platelets ≥ 100,000/μL
  • ALT & AST ≤3 x ULN or ≤5 x ULN if known hepatic metastases
  • Serum bilirubin within normal limits (WNL) or ≤1.5 x the ULN in patients with liver metastases; or total bilirubin ≤3.0 x ULN with direct bilirubin WNL in patients with well documented Gilbert's Syndrome.
  • Serum creatinine ≤1.5 x the ULN and a calculated creatinine clearance (CrCl) ≥45 mL/min by the Cockcroft-Gault method.
  • Left ventricular ejection fraction (LVEF) WNL of the institution as determined by multiple uptake gated acquisition (MUGA) or echocardiography (ECHO) (applies to Arm D only).
  • Female patients, ≥18, (not of childbearing potential and fertile female patients of childbearing potential) who agree to use adequate contraceptive measures from 2 weeks prior to the study and until 1 month after study treatment discontinuation, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start.
  • Predicted life expectancy ≥ 12 weeks

Exclusion

  • Use of a study drug (approved or investigational drug therapy) ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of study treatment. For study drugs for which 5 half-lives is ≤21 days, a minimum of 10 days between termination of the study drug and administration of study treatment is required.
  • Major surgical procedures ≤ 28 days of beginning study, or minor surgical procedures ≤7 days. No waiting period following port-a-cath placement, or any other central venous access placement.
  • Grade >1 toxicity from prior therapy (except alopecia or anorexia).
  • Known malignant CNS disease other than neurologically stable, treated brain metastases, defined as metastasis having no evidence of progression or haemorrhage after treatment for at least 2 weeks (including brain radiotherapy). Must be off any systemic corticosteroids for the treatment of brain metastases for at least 14 days prior to enrolment.
  • Patient has had prescription or non-prescription drugs or other products (i.e.grapefruit juice) known to be sensitive CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors or inducers of CYP3A4 which cannot be discontinued 2 weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after last dose of study drug.
  • Caution should be exercised when inhibitors or substrates of P-gP, substrates of CYP1A2 with a narrow therapeutic range, sensitive substrates of CYP2C19 or CYP2C19 substrates with a narrow therapeutic range are administered with AZD1775.
  • Herbal medications should be discontinued 7 days prior to the first dose of study treatment.
  • Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) ≥ Class 2:
  • Unstable angina pectoris
  • Congestive heart failure
  • Acute myocardial infarction
  • Conduction abnormality not controlled with pacemaker or medication
  • Significant ventricular or supraventricular arrhythmias (patients with chronic rate controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible).
  • AZD1775 should not be given to patients who have a history of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected. AZD1775 has not been studied in patients with ventricular arrhythmias or recent myocardial infarction.
  • Corrected QT interval (QTc) >470 msec at study entry or congenital long QT syndrome.
  • Pregnant or lactating.
  • Serious active infection at the time of enrolment, or another serious underlying medical condition that would impair the patient's ability to receive study treatment.
  • Presence of other active cancers, or history of treatment for invasive cancer within 3 years. Patients with Stage I cancer who have received definitive local treatment within 3 years, and whom are considered unlikely to recur, are eligible. Patients with previously treated in-situ carcinoma (i.e., non-invasive) are eligible, as are patients with prior non-melanoma skin cancers.

Locations

  • Research Site accepting new patients
    San Francisco, California, 94158, United States
  • Research Site accepting new patients
    Los Angeles, California, 90095, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AstraZeneca
ID
NCT02272790
Phase
Phase 2
Lead Scientist
Lee-May Chen
Study Type
Interventional
Last Updated
November 14, 2017
I’m interested in this study!